利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.016 秒)

    Reagents and methods for detecting influenza virus proteins
    1.
    发明授权
    Reagents and methods for detecting influenza virus proteins 有权
    用于检测流感病毒蛋白质的试剂和方法

    公开(公告)号：US08926982B2

    公开(公告)日：2015-01-06

    申请号：US13322459

    申请日：2010-05-28

    申请人： Xuguang Li ,  Runtao He ,  Gary Van Domselaar

    发明人： Xuguang Li ,  Runtao He ,  Gary Van Domselaar

    IPC分类号： A61K39/145 ,  C07K16/10 ,  G01N33/569 ,  G01N33/573 ,  C12N9/24 ,  A61K39/00

    CPC分类号： G01N33/56983 ,  A61K39/12 ,  A61K39/145 ,  A61K2039/505 ,  A61K2039/55566 ,  A61K2039/6081 ,  C07K16/1018 ,  C07K16/40 ,  C07K2317/34 ,  C12N9/2402 ,  C12N2760/16134 ,  C12Y302/01018 ,  G01N33/573 ,  G01N2333/924 ,  G01N2333/9506

    摘要： Two universally conserved sequences from influenza type A neuraminidases were identified by large scale sequence analysis then chemically modified and conjugated to carrier proteins to generate mono-specific and monoclonal antibodies. The two antibodies, one targeting the N-terminus of the type A neuraminidase and the other sequence close to enzymatic active site, were capable of binding to all 9 subtypes of neuraminidase while demonstrating remarkable specificity against the viral neuraminidase sequences since no cross-reactivity against allantoic proteins was observed. Quantitative analyses of NA using slot blot suggest that the antibodies can be used for NA antigen quantitation in vaccines. These represent the first time the antibody-based immunoassay can be used for NA quantitative determination.

    摘要翻译： 通过大规模序列分析鉴定了来自甲型流感A型神经氨酸酶的两种普遍保守的序列，然后化学修饰并与载体蛋白缀合以产生单特异性和单克隆抗体。 靶向A型神经氨酸酶的N末端的两种抗体和接近酶活性位点的其他序列能够结合所有9种亚型的神经氨酸酶，同时显示出对病毒神经氨酸酶序列的显着特异性，因为没有交叉反应 观察尿囊蛋白。 使用狭缝印迹的NA的定量分析表明抗体可用于疫苗中的NA抗原定量。 这些代表了首次基于抗体的免疫测定可用于NA定量测定。

    REAGENTS AND METHODS FOR DETECTING INFLUENZA VIRUS PROTEINS
    2.
    发明申请
    REAGENTS AND METHODS FOR DETECTING INFLUENZA VIRUS PROTEINS 审中-公开
    用于检测流感病毒蛋白的试剂和方法

    公开(公告)号：US20120141519A1

    公开(公告)日：2012-06-07

    申请号：US13322459

    申请日：2010-05-28

    申请人： Xuguang Li ,  Runtao He ,  Gary Van Domselaar

    发明人： Xuguang Li ,  Runtao He ,  Gary Van Domselaar

    IPC分类号： A61K39/145 ,  C07K16/10 ,  C07K1/00 ,  A61P31/16 ,  C12P21/08 ,  G01N33/573 ,  C12N9/96 ,  A61P37/04

    CPC分类号： G01N33/56983 ,  A61K39/12 ,  A61K39/145 ,  A61K2039/505 ,  A61K2039/55566 ,  A61K2039/6081 ,  C07K16/1018 ,  C07K16/40 ,  C07K2317/34 ,  C12N9/2402 ,  C12N2760/16134 ,  C12Y302/01018 ,  G01N33/573 ,  G01N2333/924 ,  G01N2333/9506

    摘要： Two universally conserved sequences from influenza type A neuraminidases were identified by large scale sequence analysis then chemically modified and conjugated to carrier proteins to generate mono-specific and monoclonal antibodies. The two antibodies, one targeting the N-terminus of the type A neuraminidase and the other sequence close to enzymatic active site, were capable of binding to all 9 subtypes of neuraminidase while demonstrating remarkable specificity against the viral neuraminidase sequences since no cross-reactivity against allantoic proteins was observed. Quantitative analyses of NA using slot blot suggest that the antibodies can be used for NA antigen quantitation in vaccines. These represent the first time the antibody-based immunoassay can be used for NA quantitative determination.

    摘要翻译： 通过大规模序列分析鉴定了来自甲型流感A型神经氨酸酶的两种普遍保守的序列，然后化学修饰并与载体蛋白缀合以产生单特异性和单克隆抗体。 靶向A型神经氨酸酶的N末端的两种抗体和接近酶活性位点的其他序列能够结合所有9种亚型的神经氨酸酶，同时显示出对病毒神经氨酸酶序列的显着特异性，因为没有交叉反应 观察尿囊蛋白。 使用狭缝印迹的NA的定量分析表明抗体可用于疫苗中的NA抗原定量。 这些代表了首次基于抗体的免疫测定可用于NA定量测定。

    Reagents and methods for detecting influenza virus proteins
    5.
    发明授权
    Reagents and methods for detecting influenza virus proteins 有权
    用于检测流感病毒蛋白质的试剂和方法

    公开(公告)号：US08669046B2

    公开(公告)日：2014-03-11

    申请号：US12920838

    申请日：2009-03-10

    申请人： Xuguang (Sean) Li ,  Runtao He ,  Gary Van Domselaar

    发明人： Xuguang (Sean) Li ,  Runtao He ,  Gary Van Domselaar

    IPC分类号： C07K16/10 ,  G01N33/569 ,  C07K7/08 ,  C07K17/06 ,  C12Q1/70 ,  A61K39/145

    CPC分类号： C07K16/1018 ,  C07K14/005 ,  C12N2760/16122 ,  G01N2333/11

    摘要： Antibodies that specifically bind to a peptide having an amino acid sequence as found at the N-terminus of the HA2 fusion peptide of the influenza A virus may be raised by inoculating a mammal with a conjugate of the peptide. In one embodiment, the conjugate comprises the peptide linked to a spacer (e.g. 6-aminocaproic acid) and a carrier protein (e.g. KLH). The antibodies may be used as a universal reagent for detecting HA proteins of influenza viruses. The antibodies are useful as versatile reagents for laboratory research and vaccine potency determination, especially in the event of pandemic influenza outbreaks.

    摘要翻译： 可以通过用肽的缀合物接种哺乳动物来提高特异性结合具有在甲型流感病毒的HA2融合肽的N-末端的氨基酸序列的肽的抗体。 在一个实施方案中，缀合物包含连接到间隔基（例如6-氨基己酸）和载体蛋白（例如KLH）的肽。 抗体可以用作检测流感病毒HA蛋白的通用试剂。 抗体可用作实验室研究和疫苗效力测定的多用试剂，特别是在大流行性流感爆发时。

    REAGENTS AND METHODS FOR DETECTING INFLUENZA VIRUS PROTEINS
    6.
    发明申请
    REAGENTS AND METHODS FOR DETECTING INFLUENZA VIRUS PROTEINS 有权
    用于检测流感病毒蛋白的试剂和方法

    公开(公告)号：US20110059472A1

    公开(公告)日：2011-03-10

    申请号：US12920838

    申请日：2009-03-10

    申请人： Xuguang (Sean) Li ,  Runtao He ,  Gary Van Domselaar

    发明人： Xuguang (Sean) Li ,  Runtao He ,  Gary Van Domselaar

    IPC分类号： G01N33/53 ,  C07K16/08 ,  C07K7/08

    CPC分类号： C07K16/1018 ,  C07K14/005 ,  C12N2760/16122 ,  G01N2333/11

    摘要： Antibodies that specifically bind to a peptide having an amino acid sequence as found at the N-terminus of the HA2 fusion peptide of the influenza A virus may be raised by inoculating a mammal with a conjugate of the peptide. In one embodiment, the conjugate comprises the peptide linked to a spacer (e.g. 6-aminocaproic acid) and a carrier protein (e.g. KLH). The antibodies may be used as a universal reagent for detecting HA proteins of influenza viruses. The antibodies are useful as versatile reagents for laboratory research and vaccine potency determination, especially in the event of pandemic influenza outbreaks.

    摘要翻译： 可以通过用肽的缀合物接种哺乳动物来提高特异性结合具有在甲型流感病毒的HA2融合肽的N-末端的氨基酸序列的肽的抗体。 在一个实施方案中，缀合物包含连接到间隔基（例如6-氨基己酸）和载体蛋白（例如KLH）的肽。 抗体可以用作检测流感病毒HA蛋白的通用试剂。 抗体可用作实验室研究和疫苗效力测定的多用试剂，特别是在大流行性流感爆发时。

    Inhibition of Feline Calicivirus
    7.
    发明申请
    Inhibition of Feline Calicivirus 审中-公开
    抑制猫杯状病毒

    公开(公告)号：US20080299105A1

    公开(公告)日：2008-12-04

    申请号：US11572282

    申请日：2005-09-13

    申请人： Runtao He

    发明人： Runtao He

    IPC分类号： A61K38/50 ,  A61P31/12

    CPC分类号： A61K38/50

    摘要： We conducted feline calicivirus (FCV) inhibition experiment with two anti-viral aminohydrolases, asparaginase and glutaminase. We found that in the presence of 8 units and 4 units/ml of asparaginase, about 90% of FCV replication was inhibited. In contrast, glutaminase showed no significant inhibition effect on the virus replication. We have also shown that asparaginase did not inhibit the replication of adenovirus suggesting that the inhibition was specific. Our results implicated that asparaginase could be used as a candidate for anti-FCV drug development.

    摘要翻译： 我们用两种抗病毒氨基水解酶，天冬酰胺酶和谷氨酰胺酶进行猫杯状病毒（FCV）抑制实验。 我们发现在8单位和4单位/ ml的天冬酰胺酶的存在下，约90％的FCV复制被抑制。 相比之下，谷氨酰胺酶对病毒复制没有显着的抑制作用。 我们还显示天冬酰胺酶不抑制腺病毒的复制，表明抑制是特异性的。 我们的研究结果表明，天冬酰胺酶可以作为抗FCV药物开发的候选者。

    Potent and Selective Inhibition by Aurinticarboxylic Acid
    8.
    发明申请
    Potent and Selective Inhibition by Aurinticarboxylic Acid 审中-公开
    Aurinticar酸的有效和选择性抑制作用

    公开(公告)号：US20110112195A1

    公开(公告)日：2011-05-12

    申请号：US11570650

    申请日：2005-06-15

    申请人： Runtao He ,  Anton Andonov ,  Jingxin Cao ,  Mike Drebot ,  Xueguang Li

    发明人： Runtao He ,  Anton Andonov ,  Jingxin Cao ,  Mike Drebot ,  Xueguang Li

    IPC分类号： A61K31/194 ,  C40B30/02

    CPC分类号： A61K31/194 ,  C12Q1/18 ,  G01N2500/00 ,  Y02A50/385 ,  Y02A50/389 ,  Y02A50/393

    摘要： The severe acute respiratory syndrome virus (SARS) is a coronavirus that instigated regional epidemics in Canada and several Asian countries in 2003. The newly identified SARS coronavirus (SARS-CoV) can be transmitted among humans and cause severe or even fatal illnesses. As preventive vaccine development takes years to complete and adverse reactions have been reported to some veterinary coronaviral vaccines, anti-viral compounds must be relentlessly pursued. In this study, we analyzed the effect of aurintricarboxylic acid (ATA) on SARS-CoV replication in cell culture, and found that ATA could drastically inhibit SARS-CoV replication, with viral production being more than 1000 fold than that in the untreated control. ATA is also shown to be an effective anti-viral for several other viruses, including West Nile Virus and variola virus.

    摘要翻译： 严重急性呼吸综合征病毒（SARS）是一种冠状病毒，其在2003年煽动了加拿大和几个亚洲国家的区域流行病。新发SARS冠状病毒（SARS-CoV）可以传播给人类，造成严重甚至致命的疾病。 由于预防性疫苗开发需要多年才能完成，有些兽医冠状病毒疫苗已经报告出不良反应，因此必须不懈地追求抗病毒化合物。 在本研究中，我们分析了神经三羧酸（ATA）对细胞培养中SARS-CoV复制的影响，发现ATA可以显着抑制SARS-CoV复制，其病毒产量比未处理对照高1000倍以上。 ATA还被证明是其他几种病毒的有效抗病毒药物，包括西尼罗河病毒和天花病毒。